The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2024 | The INHERENT network: advancing understanding of genetic modifiers in hemoglobinopathies
Petros Kountouris, PhD, The Cyprus Institute of Neurology & Genetics, Lefkosia, Cyprus, introduces INHERENT, an international network focused on studying genetic modifiers in hemoglobinopathies. The aim is to address the limitations of small sample sizes in previous studies by developing a large-scale, multiethnic genome-wide association study. At present, INHERENT involves more than 200 experts from over 100 organizations in 46 countries. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Agios Pharmaceuticals.
